Gene therapy
Topline results from a mid-stage study show that 4D Molecular Therapeutics’ investigational gene therapy cut annual rates of Eylea injections by 85% and 89% for the low and high doses, respectively.
This week, Lori, Greg and Tyler discuss the first surge of IPO activity this year plus gene therapy pricing,
CRISPR gene-editing has had its first ever approval in the UK. Will the FDA follow suit? What can patients expect the price tag to be?
PRESS RELEASES